PLURI INC (PLUR) Stock Price & Overview
NASDAQ:PLUR • US72942G2030
Current stock price
The current stock price of PLUR is 3.35 USD. Today PLUR is up by 0.12%. In the past month the price increased by 9.84%. In the past year, price decreased by -39.75%.
PLUR Key Statistics
- Market Cap
- 33.668M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.27
- Dividend Yield
- N/A
PLUR Stock Performance
PLUR Stock Chart
PLUR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PLUR. When comparing the yearly performance of all stocks, PLUR is a bad performer in the overall market: 86.17% of all stocks are doing better.
PLUR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLUR. PLUR has a bad profitability rating. Also its financial health evaluation is rather negative.
PLUR Earnings
On February 12, 2026 PLUR reported an EPS of -0.71 and a revenue of 198.00K. The company missed EPS expectations (-7.09% surprise) and missed revenue expectations (-69.57% surprise).
PLUR Forecast & Estimates
7 analysts have analysed PLUR and the average price target is 12.24 USD. This implies a price increase of 265.37% is expected in the next year compared to the current price of 3.35.
For the next year, analysts expect an EPS growth of 12.2% and a revenue growth 63.28% for PLUR
PLUR Groups
Sector & Classification
PLUR Financial Highlights
Over the last trailing twelve months PLUR reported a non-GAAP Earnings per Share(EPS) of -3.27. The EPS increased by 11.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.43% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PLUR Ownership
PLUR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PLUR
Company Profile
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
Company Info
IPO: 2007-12-10
PLURI INC
Matam Advanced Technology Park, Building No. 5
Haifa IL
Employees: 135
Phone: 972747107171
PLURI INC / PLUR FAQ
What does PLURI INC do?
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The firm has a portfolio of over 140 granted patents in approximately 52 countries.
Can you provide the latest stock price for PLURI INC?
The current stock price of PLUR is 3.35 USD. The price increased by 0.12% in the last trading session.
Does PLURI INC pay dividends?
PLUR does not pay a dividend.
How is the ChartMill rating for PLURI INC?
PLUR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of PLURI INC (PLUR) based on its PE ratio?
PLURI INC (PLUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.27).
Should I buy PLUR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PLUR.
Can you provide the number of employees for PLURI INC?
PLURI INC (PLUR) currently has 135 employees.